Is VEGF a predictive biomarker to anti-angiogenic therapy?

Critical Reviews in Oncology/Hematology

Volumn 79, Issue 2, 2011, Pages 103-111

  Otrock, Zaher K ^a   Hatoum, Hassan A ^a   Musallam, Khaled M ^a   Awada, Ahmad H ^b   Shamseddine, Ali I ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Angiogenesis; Anti angiogenic therapy; Biomarker; Response; Review; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CARBOPLATIN; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; SORAFENIB; STI 157; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTINEOPLASTIC ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; COLORECTAL CANCER; COLORECTAL CARCINOMA; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVIEW; UTERINE CERVIX CANCER;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PREDICTIVE VALUE OF TESTS; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 79960160320     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.07.008     Document Type: Review

References (85)

1. Risau W. Mechanisms of angiogenesis. Nature 1997, 386:671-674.
2. Folkman J. What is the evidence that tumors are angiogenesis dependent?. J Natl Cancer Inst 1990, 82:4-6.
3. Papetti M., Herman I.M. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002, 282:C947-C970.
4. Presta M., Dell'Era P., Mitola S., Moroni E., Ronca R., Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005, 16:159-178.
5. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
6. Duda D.G., Ancukiewicz M., Jain R.K. Biomarkers of antiangiogenic therapy: how do we move from candidate biomarkers to valid biomarkers?. J Clin Oncol 2010, 28:183-185.
7. McShane L.M., Altman D.G., Sauerbrei W., et al. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005, 2:416-422.
8. Jain R.K., Duda D.G., Willett C.G., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
9. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003, 3:401-410.
10. Dvorak H.F. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
11. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
12. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001, 26:25-35.
13. Otrock Z.K., Makarem J.A., Shamseddine A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood Cells Mol Dis 2007, 38:258-268.
14. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
15. Hicklin D.J., Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005, 23:1011-1027.
16. Brown L.F., Detmar M., Claffey K., et al. Vascular permeability factor/vascular endothelial growth factor: a multifunctional angiogenic cytokine. EXS 1997, 79:233-269.
17. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995, 146:1029-1039.
18. Anderson K.C. Multiple myeloma. Advances in disease biology: therapeutic implications. Semin Hematol 2001, 38(2 (Suppl. 3)):6-10.
19. Bellamy W.T., Richter L., Frutiger Y., Grogan T.M. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999, 59:728-733.
20. Chen H., Treweeke A.T., West D.C., et al. In vitro and in vivo production of vascular endothelial growth factor by chronic lymphocytic leukemia cells. Blood 2000, 96:3181-3187.
21. Foss H.D., Araujo I., Demel G., Klotzbach H., Hummel M., Stein H. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997, 183:44-50.
22. Kini A.R., Peterson L.A., Tallman M.S., Lingen M.W. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001, 97:3919-3924.
23. Brown L.F., Berse B., Jackman R.W., et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995, 26:86-91.
24. Guidi A.J., Abu-Jawdeh G., Berse B., et al. Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 1995, 87:1237-1245.
25. Wong M.P., Cheung N., Yuen S.T., Leung S.Y., Chung L.P. Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression. Int J Cancer 1999, 81:845-850.
26. Werther K., Christensen I.J., Nielsen H.J. Determination of vascular endothelial growth factor (VEGF) in circulating blood: significance of VEGF in various leucocytes and platelets. Scand J Clin Lab Invest 2002, 62:343-350.
27. Kusumanto Y.H., Dam W.A., Hospers G.A., Meijer C., Mulder N.H. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis 2003, 6:283-287.
28. George M.L., Eccles S.A., Tutton M.G., Abulafi A.M., Swift R.I. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging?. Clin Cancer Res 2000, 6:3147-3152.
29. Salven P., Orpana A., Joensuu H. Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res 1999, 5:487-491.
30. Poon R.T., Lau C.P., Cheung S.T., Yu W.C., Fan S.T. Quantitative correlation of serum levels and tumor expression of vascular endothelial growth factor in patients with hepatocellular carcinoma. Cancer Res 2003, 63:3121-3126.
31. Inoue K., Slaton J.W., Karashima T., et al. The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 2000, 6:4866-4873.
32. Yoshiji H., Gomez D.E., Shibuya M., Thorgeirsson U.P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res 1996, 56:2013-2016.
33. Amaya H., Tanigawa N., Lu C., et al. Association of vascular endothelial growth factor expression with tumor angiogenesis, survival and thymidine phosphorylase/platelet-derived endothelial cell growth factor expression in human colorectal cancer. Cancer Lett 1997, 119:227-235.
34. Eisma R.J., Spiro J.D., Kreutzer D.L. Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 1997, 174:513-517.
35. O'Byrne K.J., Koukourakis M.I., Giatromanolaki A., et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000, 82:1427-1432.
36. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87:506-516.
37. Jacobsen J., Rasmuson T., Grankvist K., Ljungberg B. Vascular endothelial growth factor as prognostic factor in renal cell carcinoma. J Urol 2000, 163:343-347.
38. Meunier-Carpentier S., Dales J.P., Djemli A., et al. Comparison of the prognosis indication of VEGFR-1 and VEGFR-2 and Tie2 receptor expression in breast carcinoma. Int J Oncol 2005, 26:977-984.
39. Seto T., Higashiyama M., Funai H., et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006, 53:91-96.
40. Chung G.G., Yoon H.H., Zerkowski M.P., et al. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray. Cancer 2006, 106:1677-1684.
41. Presta L.G., Chen H., O'Connor S.J., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997, 57:4593-4599.
42. Margolin K., Gordon M.S., Holmgren E., et al. Phase Ib trial of intravenous recombinant humanized monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001, 19:851-856.
43. Gordon M.S., Margolin K., Talpaz M., et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001, 19:843-850.
44. Willett C.G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
45. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
46. Kabbinavar F., Hurwitz H.I., Fehrenbacher L., et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003, 21:60-65.
47. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
48. Lyseng-Williamson K.A., Robinson D.M. Spotlight on bevacizumab in advanced colorectal cancer, breast cancer, and non-small cell lung cancer. BioDrugs 2006, 20:193-195.
49. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003, 349:427-434.
50. Miller K.D., Chap L.I., Holmes F.A., et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005, 23:792-799.
51. Jubb A.M., Hurwitz H.I., Bai W., et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
52. Willett C.G., Boucher Y., Duda D.G., et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
53. Bando H., Weich H.A., Brokelmann M., et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br J Cancer 2005, 92:553-561.
54. Miller K. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005, 94(Suppl. 6). [abstr. 3].
55. Miller K.D. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003, 3:421-422.
56. Sachdev J.C., Jahanzeb M. Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 2008, 8:402-410.
57. Hillan K.J., Koeppen H.K.W., Tobin P., et al. The role of VEGF expression in response to bevacizumab plus capecitabine in metastatic breast cancer (MBC). Proc Am Soc Clin Oncol 2003, 22:191. [abstr. 766].
58. Holden S.N., Ryan E., Kearns A., Holmgren E., Hurwitz H. Benefit from bevacizumab (BV) is independent of pretreatment plasma vascular endothelial growth factor-A (pl-VEGF) in patients (pts) with metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol 2005, 23:259. [abstr. 3555].
59. Kindler H.L., Friberg G., Singh D.A., et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 2005, 23:8033-8040.
60. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003, 101:3597-3605.
61. Sun L., Liang C., Shirazian S., et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003, 46:1116-1119.
62. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
63. Wood J.M., Bold G., Buchdunger E., et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000, 60:2178-2189.
64. Hennequin L.F., Stokes E.S., Thomas A.P., et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002, 45:1300-1312.
65. Wedge S.R., Ogilvie D.J., Dukes M., et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002, 62:4645-4655.
66. O'Farrell A.M., Deprimo S.E., Manning W.C., et al. Analysis of biomarkers of SU11248 action in an exploratory study in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003, 22:234. [Abstr 939].
67. Volm M., Koomägi R., Mattern J. Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 1997, 74:64-68.
68. Raymond E., Faivre S., Vera K., et al. Final results of a phase I and pharmacokinetic study of SU11248, a novel multi-target tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2003, 22:192. [abstr. 769].
69. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006, 24:16-24.
70. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006, 24:25-35.
71. Rudge J.S., Holash J., Hylton D., et al. Inaugural article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA 2007, 104:18363-18370.
72. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007, 104:17069-17074.
73. Drevs J., Zirrgiebel U., Schmidt-Gersbach C.I., et al. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials. Ann Oncol 2005, 16:558-565.
74. Conrad C., Friedman H., Reardon D., et al. A phase I/II trial of single-agent PTK 787/ZK 222584 (PTK/ZK), a novel, oral angiogenesis inhibitor, in patients with recurrent glioblastoma multiforme (GBM). Proc Am Soc Clin Oncol 2004, 22(Suppl. 14). [abstr. 1512].
75. Thomas A.L., Morgan B., Horsfield M.A., et al. Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J Clin Oncol 2005, 23:4162-4171.
76. Mross K., Drevs J., Müller M., et al. Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours. Eur J Cancer 2005, 41:1291-1299.
77. Hecht J.R., Trarbach T., Jaeger E., et al. Randomized, double-blind, placebo-controlled, phase III study in patients (Pts) with metastatic adenocarcinoma of the colon or rectum receiving first-line chemotherapy with oxaliplatin/5-fluorouracil/leucovorin and PTK787/ZK 222584 or placebo (CONFIRM-1). Proc Am Soc Clin Oncol 2005, 23(Suppl. 16). [abstr. LBA3].
78. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 2009, 27:3312-3318.
79. McCarty M.F., Wey J., Stoeltzing O., et al. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer. Mol Cancer Ther 2004, 3:1041-1048.
80. Drevs J., Konerding M.A., Wolloscheck T., et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004, 7:347-354.
81. Matsumori Y., Yano S., Goto H., et al. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. Oncol Res 2006, 16:15-26.
82. Siemann D.W., Norris C.M., Ryan A., Shi W. Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474). Anticancer Res 2009, 29:1987-1992.
83. Hanrahan E.O., Ryan A.J., Mann H., et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15:3600-3609.
84. Dev I.K., Dornsife R.E., Hopper T.M., et al. Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. Br J Cancer 2004, 91:1391-1398.
85. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.